Cargando…
Benefits and harms of direct oral anticoagulation and low molecular weight heparin for thromboprophylaxis in patients undergoing non-cardiac surgery: systematic review and network meta-analysis of randomised trials
OBJECTIVE: To systematically compare the effect of direct oral anticoagulants and low molecular weight heparin for thromboprophylaxis on the benefits and harms to patients undergoing non-cardiac surgery. DESIGN: Systematic review and network meta-analysis of randomised controlled trials. DATA SOURCE...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905353/ https://www.ncbi.nlm.nih.gov/pubmed/35264372 http://dx.doi.org/10.1136/bmj-2021-066785 |
_version_ | 1784665167593734144 |
---|---|
author | Marcucci, Maura Etxeandia-Ikobaltzeta, Itziar Yang, Stephen Germini, Federico Gupta, Shyla Agarwal, Arnav Ventresca, Matthew Tang, Shaowen Morgano, Gian Paolo Wang, Mengxiao Ahmed, Muhammad Muneeb Neumann, Ignacio Izcovich, Ariel Criniti, Juan Popoff, Federico Devereaux, P J Dahm, Philipp Anderson, David Lavikainen, Lauri I Tikkinen, Kari A O Guyatt, Gordon H Schünemann, Holger J Violette, Philippe D |
author_facet | Marcucci, Maura Etxeandia-Ikobaltzeta, Itziar Yang, Stephen Germini, Federico Gupta, Shyla Agarwal, Arnav Ventresca, Matthew Tang, Shaowen Morgano, Gian Paolo Wang, Mengxiao Ahmed, Muhammad Muneeb Neumann, Ignacio Izcovich, Ariel Criniti, Juan Popoff, Federico Devereaux, P J Dahm, Philipp Anderson, David Lavikainen, Lauri I Tikkinen, Kari A O Guyatt, Gordon H Schünemann, Holger J Violette, Philippe D |
author_sort | Marcucci, Maura |
collection | PubMed |
description | OBJECTIVE: To systematically compare the effect of direct oral anticoagulants and low molecular weight heparin for thromboprophylaxis on the benefits and harms to patients undergoing non-cardiac surgery. DESIGN: Systematic review and network meta-analysis of randomised controlled trials. DATA SOURCES: Medline, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL), up to August 2021. REVIEW METHODS: Randomised controlled trials in adults undergoing non-cardiac surgery were selected, comparing low molecular weight heparin (prophylactic (low) or higher dose) with direct oral anticoagulants or with no active treatment. Main outcomes were symptomatic venous thromboembolism, symptomatic pulmonary embolism, and major bleeding. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were used for network meta-analyses. Abstracts and full texts were screened independently in duplicate. Data were abstracted on study participants, interventions, and outcomes, and risk of bias was assessed independently in duplicate. Frequentist network meta-analysis with multivariate random effects models provided odds ratios with 95% confidence intervals, and GRADE (grading of recommendations, assessment, development, and evaluation) assessments indicated the certainty of the evidence. RESULTS: 68 randomised controlled trials were included (51 orthopaedic, 10 general, four gynaecological, two thoracic, and one urological surgery), involving 45 445 patients. Low dose (odds ratio 0.33, 95% confidence interval 0.16 to 0.67) and high dose (0.19, 0.07 to 0.54) low molecular weight heparin, and direct oral anticoagulants (0.17, 0.07 to 0.41) reduced symptomatic venous thromboembolism compared with no active treatment, with absolute risk differences of 1-100 per 1000 patients, depending on baseline risks (certainty of evidence, moderate to high). None of the active agents reduced symptomatic pulmonary embolism (certainty of evidence, low to moderate). Direct oral anticoagulants and low molecular weight heparin were associated with a 2-3-fold increase in the odds of major bleeding compared with no active treatment (certainty of evidence, moderate to high), with absolute risk differences as high as 50 per 1000 in patients at high risk. Compared with low dose low molecular weight heparin, high dose low molecular weight heparin did not reduce symptomatic venous thromboembolism (0.57, 0.26 to 1.27) but increased major bleeding (1.87, 1.06 to 3.31); direct oral anticoagulants reduced symptomatic venous thromboembolism (0.53, 0.32 to 0.89) and did not increase major bleeding (1.23, 0.89 to 1.69). CONCLUSIONS: Direct oral anticoagulants and low molecular weight heparin reduced venous thromboembolism compared with no active treatment but probably increased major bleeding to a similar extent. Direct oral anticoagulants probably prevent symptomatic venous thromboembolism to a greater extent than prophylactic low molecular weight heparin. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42018106181. |
format | Online Article Text |
id | pubmed-8905353 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89053532022-03-25 Benefits and harms of direct oral anticoagulation and low molecular weight heparin for thromboprophylaxis in patients undergoing non-cardiac surgery: systematic review and network meta-analysis of randomised trials Marcucci, Maura Etxeandia-Ikobaltzeta, Itziar Yang, Stephen Germini, Federico Gupta, Shyla Agarwal, Arnav Ventresca, Matthew Tang, Shaowen Morgano, Gian Paolo Wang, Mengxiao Ahmed, Muhammad Muneeb Neumann, Ignacio Izcovich, Ariel Criniti, Juan Popoff, Federico Devereaux, P J Dahm, Philipp Anderson, David Lavikainen, Lauri I Tikkinen, Kari A O Guyatt, Gordon H Schünemann, Holger J Violette, Philippe D BMJ Research OBJECTIVE: To systematically compare the effect of direct oral anticoagulants and low molecular weight heparin for thromboprophylaxis on the benefits and harms to patients undergoing non-cardiac surgery. DESIGN: Systematic review and network meta-analysis of randomised controlled trials. DATA SOURCES: Medline, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL), up to August 2021. REVIEW METHODS: Randomised controlled trials in adults undergoing non-cardiac surgery were selected, comparing low molecular weight heparin (prophylactic (low) or higher dose) with direct oral anticoagulants or with no active treatment. Main outcomes were symptomatic venous thromboembolism, symptomatic pulmonary embolism, and major bleeding. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were used for network meta-analyses. Abstracts and full texts were screened independently in duplicate. Data were abstracted on study participants, interventions, and outcomes, and risk of bias was assessed independently in duplicate. Frequentist network meta-analysis with multivariate random effects models provided odds ratios with 95% confidence intervals, and GRADE (grading of recommendations, assessment, development, and evaluation) assessments indicated the certainty of the evidence. RESULTS: 68 randomised controlled trials were included (51 orthopaedic, 10 general, four gynaecological, two thoracic, and one urological surgery), involving 45 445 patients. Low dose (odds ratio 0.33, 95% confidence interval 0.16 to 0.67) and high dose (0.19, 0.07 to 0.54) low molecular weight heparin, and direct oral anticoagulants (0.17, 0.07 to 0.41) reduced symptomatic venous thromboembolism compared with no active treatment, with absolute risk differences of 1-100 per 1000 patients, depending on baseline risks (certainty of evidence, moderate to high). None of the active agents reduced symptomatic pulmonary embolism (certainty of evidence, low to moderate). Direct oral anticoagulants and low molecular weight heparin were associated with a 2-3-fold increase in the odds of major bleeding compared with no active treatment (certainty of evidence, moderate to high), with absolute risk differences as high as 50 per 1000 in patients at high risk. Compared with low dose low molecular weight heparin, high dose low molecular weight heparin did not reduce symptomatic venous thromboembolism (0.57, 0.26 to 1.27) but increased major bleeding (1.87, 1.06 to 3.31); direct oral anticoagulants reduced symptomatic venous thromboembolism (0.53, 0.32 to 0.89) and did not increase major bleeding (1.23, 0.89 to 1.69). CONCLUSIONS: Direct oral anticoagulants and low molecular weight heparin reduced venous thromboembolism compared with no active treatment but probably increased major bleeding to a similar extent. Direct oral anticoagulants probably prevent symptomatic venous thromboembolism to a greater extent than prophylactic low molecular weight heparin. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42018106181. BMJ Publishing Group Ltd. 2022-03-09 /pmc/articles/PMC8905353/ /pubmed/35264372 http://dx.doi.org/10.1136/bmj-2021-066785 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Research Marcucci, Maura Etxeandia-Ikobaltzeta, Itziar Yang, Stephen Germini, Federico Gupta, Shyla Agarwal, Arnav Ventresca, Matthew Tang, Shaowen Morgano, Gian Paolo Wang, Mengxiao Ahmed, Muhammad Muneeb Neumann, Ignacio Izcovich, Ariel Criniti, Juan Popoff, Federico Devereaux, P J Dahm, Philipp Anderson, David Lavikainen, Lauri I Tikkinen, Kari A O Guyatt, Gordon H Schünemann, Holger J Violette, Philippe D Benefits and harms of direct oral anticoagulation and low molecular weight heparin for thromboprophylaxis in patients undergoing non-cardiac surgery: systematic review and network meta-analysis of randomised trials |
title | Benefits and harms of direct oral anticoagulation and low molecular weight heparin for thromboprophylaxis in patients undergoing non-cardiac surgery: systematic review and network meta-analysis of randomised trials |
title_full | Benefits and harms of direct oral anticoagulation and low molecular weight heparin for thromboprophylaxis in patients undergoing non-cardiac surgery: systematic review and network meta-analysis of randomised trials |
title_fullStr | Benefits and harms of direct oral anticoagulation and low molecular weight heparin for thromboprophylaxis in patients undergoing non-cardiac surgery: systematic review and network meta-analysis of randomised trials |
title_full_unstemmed | Benefits and harms of direct oral anticoagulation and low molecular weight heparin for thromboprophylaxis in patients undergoing non-cardiac surgery: systematic review and network meta-analysis of randomised trials |
title_short | Benefits and harms of direct oral anticoagulation and low molecular weight heparin for thromboprophylaxis in patients undergoing non-cardiac surgery: systematic review and network meta-analysis of randomised trials |
title_sort | benefits and harms of direct oral anticoagulation and low molecular weight heparin for thromboprophylaxis in patients undergoing non-cardiac surgery: systematic review and network meta-analysis of randomised trials |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905353/ https://www.ncbi.nlm.nih.gov/pubmed/35264372 http://dx.doi.org/10.1136/bmj-2021-066785 |
work_keys_str_mv | AT marcuccimaura benefitsandharmsofdirectoralanticoagulationandlowmolecularweightheparinforthromboprophylaxisinpatientsundergoingnoncardiacsurgerysystematicreviewandnetworkmetaanalysisofrandomisedtrials AT etxeandiaikobaltzetaitziar benefitsandharmsofdirectoralanticoagulationandlowmolecularweightheparinforthromboprophylaxisinpatientsundergoingnoncardiacsurgerysystematicreviewandnetworkmetaanalysisofrandomisedtrials AT yangstephen benefitsandharmsofdirectoralanticoagulationandlowmolecularweightheparinforthromboprophylaxisinpatientsundergoingnoncardiacsurgerysystematicreviewandnetworkmetaanalysisofrandomisedtrials AT germinifederico benefitsandharmsofdirectoralanticoagulationandlowmolecularweightheparinforthromboprophylaxisinpatientsundergoingnoncardiacsurgerysystematicreviewandnetworkmetaanalysisofrandomisedtrials AT guptashyla benefitsandharmsofdirectoralanticoagulationandlowmolecularweightheparinforthromboprophylaxisinpatientsundergoingnoncardiacsurgerysystematicreviewandnetworkmetaanalysisofrandomisedtrials AT agarwalarnav benefitsandharmsofdirectoralanticoagulationandlowmolecularweightheparinforthromboprophylaxisinpatientsundergoingnoncardiacsurgerysystematicreviewandnetworkmetaanalysisofrandomisedtrials AT ventrescamatthew benefitsandharmsofdirectoralanticoagulationandlowmolecularweightheparinforthromboprophylaxisinpatientsundergoingnoncardiacsurgerysystematicreviewandnetworkmetaanalysisofrandomisedtrials AT tangshaowen benefitsandharmsofdirectoralanticoagulationandlowmolecularweightheparinforthromboprophylaxisinpatientsundergoingnoncardiacsurgerysystematicreviewandnetworkmetaanalysisofrandomisedtrials AT morganogianpaolo benefitsandharmsofdirectoralanticoagulationandlowmolecularweightheparinforthromboprophylaxisinpatientsundergoingnoncardiacsurgerysystematicreviewandnetworkmetaanalysisofrandomisedtrials AT wangmengxiao benefitsandharmsofdirectoralanticoagulationandlowmolecularweightheparinforthromboprophylaxisinpatientsundergoingnoncardiacsurgerysystematicreviewandnetworkmetaanalysisofrandomisedtrials AT ahmedmuhammadmuneeb benefitsandharmsofdirectoralanticoagulationandlowmolecularweightheparinforthromboprophylaxisinpatientsundergoingnoncardiacsurgerysystematicreviewandnetworkmetaanalysisofrandomisedtrials AT neumannignacio benefitsandharmsofdirectoralanticoagulationandlowmolecularweightheparinforthromboprophylaxisinpatientsundergoingnoncardiacsurgerysystematicreviewandnetworkmetaanalysisofrandomisedtrials AT izcovichariel benefitsandharmsofdirectoralanticoagulationandlowmolecularweightheparinforthromboprophylaxisinpatientsundergoingnoncardiacsurgerysystematicreviewandnetworkmetaanalysisofrandomisedtrials AT crinitijuan benefitsandharmsofdirectoralanticoagulationandlowmolecularweightheparinforthromboprophylaxisinpatientsundergoingnoncardiacsurgerysystematicreviewandnetworkmetaanalysisofrandomisedtrials AT popofffederico benefitsandharmsofdirectoralanticoagulationandlowmolecularweightheparinforthromboprophylaxisinpatientsundergoingnoncardiacsurgerysystematicreviewandnetworkmetaanalysisofrandomisedtrials AT devereauxpj benefitsandharmsofdirectoralanticoagulationandlowmolecularweightheparinforthromboprophylaxisinpatientsundergoingnoncardiacsurgerysystematicreviewandnetworkmetaanalysisofrandomisedtrials AT dahmphilipp benefitsandharmsofdirectoralanticoagulationandlowmolecularweightheparinforthromboprophylaxisinpatientsundergoingnoncardiacsurgerysystematicreviewandnetworkmetaanalysisofrandomisedtrials AT andersondavid benefitsandharmsofdirectoralanticoagulationandlowmolecularweightheparinforthromboprophylaxisinpatientsundergoingnoncardiacsurgerysystematicreviewandnetworkmetaanalysisofrandomisedtrials AT lavikainenlaurii benefitsandharmsofdirectoralanticoagulationandlowmolecularweightheparinforthromboprophylaxisinpatientsundergoingnoncardiacsurgerysystematicreviewandnetworkmetaanalysisofrandomisedtrials AT tikkinenkariao benefitsandharmsofdirectoralanticoagulationandlowmolecularweightheparinforthromboprophylaxisinpatientsundergoingnoncardiacsurgerysystematicreviewandnetworkmetaanalysisofrandomisedtrials AT guyattgordonh benefitsandharmsofdirectoralanticoagulationandlowmolecularweightheparinforthromboprophylaxisinpatientsundergoingnoncardiacsurgerysystematicreviewandnetworkmetaanalysisofrandomisedtrials AT schunemannholgerj benefitsandharmsofdirectoralanticoagulationandlowmolecularweightheparinforthromboprophylaxisinpatientsundergoingnoncardiacsurgerysystematicreviewandnetworkmetaanalysisofrandomisedtrials AT violettephilipped benefitsandharmsofdirectoralanticoagulationandlowmolecularweightheparinforthromboprophylaxisinpatientsundergoingnoncardiacsurgerysystematicreviewandnetworkmetaanalysisofrandomisedtrials |